ABILIFY Drug Patent Profile

When do Abilify patents expire, and what generic alternatives are available?

Abilify is a drug marketed by Otsuka and Otsuka Pharm Co Ltd and is included in seven NDAs. There are thirty-seven patents protecting this drug and three Paragraph IV challenges.

The generic ingredient in ABILIFY is aripiprazole. Fifty suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Abilify

A generic version of ABILIFY was approved as aripiprazole by ALEMBIC on April 28^th, 2015.

Summary for ABILIFY

US Patents:	2
Applicants:	2
NDAs:	7
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ABILIFY

Paragraph IV (Patent) Challenges for ABILIFY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ABILIFY	Oral Solution	aripiprazole	1 mg/mL	021713	1	2007-12-20
ABILIFY	Tablets	aripiprazole	2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg	021436	8	2006-11-15
ABILIFY	Orally Disintegrating Tablets	aripiprazole	10 mg, 15 mg, 20 mg and 30 mg	021729	1	2006-11-15

US Patents and Regulatory Information for ABILIFY

ABILIFY is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-006	Nov 13, 2017		DISCN	Yes	No			Y
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-001	Nov 13, 2017		DISCN	Yes	No
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-006	Nov 13, 2017		DISCN	Yes	No			Y

International Patents for ABILIFY

See the table below for patents covering ABILIFY around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	376432
Austria	376433
Austria	376434

Supplementary Protection Certificates for ABILIFY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1675573	300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
1675573	92427	Luxembourg		PRODUCT NAME: ARIPIPRAZOLE
0367141	SPC/GB04/039	United Kingdom		PRODUCT NAME: ARIPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/04/276/001 20040604; UK EU/1/04/276/002 20040604; UK EU/1/04/276/003 20040604; UK EU/1/04/276/004 20040604; UK EU/1/04/276/005 20040604; UK EU/1/04/276/006 20040604; UK EU/1/04/276/007 20040604; UK EU/1/04/276/008 20040604; UK EU/1/04/276/009 20040604; UK EU/1/04/276/010 20040604; UK EU/1/04/276/011 20040604; UK EU/1/04/276/012 20040604; UK EU/1/04/276/013 20040604; UK EU/1/04/276/014 20040604; UK EU/1/04/276/015 20040604; UK EU/1/04/276/016 20040604; UK EU/1/04/276/017 20040604; UK EU/1/04/276/018 20040604; UK EU/1/04/276/019 20040604; UK EU/1/04/276/020 20040604

Investment Scenario and Fundamentals Analysis for ABILIFY

Last updated: February 20, 2026

What Is ABILIFY?

ABILIFY is the brand name for aripiprazole, an antipsychotic medication approved for treating schizophrenia, bipolar disorder, and as an adjunct for major depressive disorder. Developed by Otsuka Pharmaceutical and marketed by Bristol-Myers Squibb (initially) and later by other licensees, ABILIFY became one of the best-selling drugs globally.

Market Overview

Sales and Market Penetration

• Global sales peaked at $7.5 billion in 2019 (IQVIA, 2022).
• The drug's revenues declined to approximately $5.2 billion in 2022 following generic entry and patent expirations.
• Major markets include the U.S., Europe, and Japan, with the U.S. accounting for around 50% of sales.

Patent Timeline & Generic Competition

• Original patents expired in the U.S. in 2015; in Europe, in 2019.
• Multiple generics entered the U.S. market post-2015, resulting in a 60–70% price erosion.
• Branded sales now diminished but still contribute through newer formulations.

Fundamentals Analysis

Revenue Drivers

• Established label: Schizophrenia and bipolar disorder.
• Growing off-label use: Adjunctive treatment for depression and irritability in autism.
• Uptake of long-acting injectable formulations (e.g., ABILIFY MAINTENA) provides new revenue streams.
• Market saturation in developed economies is a concern; growth potential relies on demographic trends and new indications.

Cost Structure

• R&D expenses: Substantial upfront investment for new formulations and indications.
• Manufacturing costs: Low to moderate, with established supply chains.
• Marketing and distribution costs: High in first markets but declining after patent expiry.

Competition

Competitor	Product	Key Features	Market Share (2019)
Risperdal (Janssen)	Risperidone	Similar antipsychotic, patent expired	12%
Latuda (Lurasidone)	Lurasidone	Approved for bipolar and depression	8%
Seroquel (AstraZeneca)	Quetiapine	Broad-spectrum antipsychotic	10%

• Generic competition has eroded the market value of ABILIFY significantly.

Pharmacological Profile & Specific Advantages

• Partial agonist at dopamine D2 and serotonin 5-HT1A receptors.
• Antagonist at serotonin 5-HT2A receptors.
• Favorable side-effect profile relative to competitors—less weight gain.

Investment Outlook

Short-term

• Revenue decline expected due to patent expiration and generics.
• Growth prospects hinge on the success of new formulations.

Long-term

• Potential growth from expanded indications, especially in autism spectrum disorder and depression.
• Development of biosimilars and alternative formulations could influence sales.

Risks

• Patent litigation and market access barriers.
• Competitive pressure from newer antipsychotics with better efficacy or safety profiles.
• Shifts in prescribing guidelines towards other treatments.

Opportunities

• Launch of long-acting injectable formulations.
• Expanding use in pediatric and adolescent populations.
• Strategic alliances for new indications.

Financial Metrics and Valuation

• 2022 revenue: ~$5.2 billion.
• EBITDA margins: Approximately 30-35%.
• Market cap of key licensees: BMS (~$150 billion), Otsuka's valuation is private but significant in Japan.

Valuation models should incorporate declining sales post-patent expiry, potential growth from new indications, and regulatory risks.

Key Takeaways

• ABILIFY's peak sales were in 2019, with decline driven by patent expiration and market saturation.
• Growth now depends on successful rollout of extended-release formulations and new uses.
• Competition from generics and biosimilars remains a primary risk.
• The drug’s pharmacological profile and side-effect advantages sustain its relevance.
• Investment decisions should consider the timing and success of expected product pipeline developments.

FAQs

1. What is the expected revenue trend for ABILIFY over the next five years?
Revenue is projected to decline gradually due to generic competition unless new formulations or indications generate offsetting sales.

2. How does the patent expiration impact ABILIFY’s market exclusivity?
Patents expired in key markets between 2015 and 2019, enabling generics to enter, significantly reducing brand sales.

3. Are there any upcoming formulations that could revive ABILIFY’s sales?
Yes, long-acting injectable versions like ABILIFY MAINTENA can sustain or grow sales if marketed effectively.

4. What are the primary risks associated with investing in ABILIFY?
Patent challenges, generic erosion, regulatory hurdles for new indications, and competition from newer drugs.

5. What markets offer the highest growth potential for ABILIFY?
Emerging markets and expanding indications in pediatric psychiatry and depression may provide growth opportunities.

References

1. IQVIA. (2022). Pharmaceutical Market Analysis.
2. U.S. Food and Drug Administration. (2015). Patent and Exclusivity Data for ABILIFY.
3. European Medicines Agency. (2019). Approval and Patent Timeline for ABILIFY.
4. MarketWatch. (2022). Top Pharmaceutical Sales Data.
5. Otsuka Pharmaceutical. (2022). Annual Report.